Table S2. MRM (Multiple reaction monitoring) parameters of the target compounds Compound name ChEBI Abbreviation ID molecular formula MW g/mole precursor ion (m/z) product ion (m/z) Dwell time CE (msec)
Table S2. Age-adjusted Incidence Rates and Incidence Rate Ratios of Overall Type II Endometrial Cancer by Race/Ethnicity for 2004–2009 (Period 1) and 2010–2015 (Period 2) N IR (95% CI) IRR (95% CI) P value Overall
Table S2. Comparisonsa of minimally-adjusted mean APC expressionb in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients (n = 104), by selected participant characteristics Proportional differencec (%) P-value Proportional differencec (%) P-value Proportional differencec (%) P-value 47 - 54 34 2,502 (2,148, 2,856) - 979 (817, 1,141) - 1,389 (1,157, 1,621) - 55 - 62 35 2,576 (2,224, 2,928) 3.0 1,040 (879, 1,201) 6.3 1,384 (1,153, 1,615) -0.3 63 - 75Sex Male 35 48 2,457 2,714 (2,106, 2,808) (2,338, 3,089) -1.8 - 0.88 1,026 1,074 (866, 1,186) (905, 1,242) 4.8 - 0.68 1,275 1,483 (1,045, 1,505) (1,261, 1,706) -8.2 - 0.51 Female 56 2,338 (1,990, 2,685) -13.9 0.15 966 (810, 1,122) -10.0 0.36 1,231 (1,026, 1,437) -17.0 0.10 Regulard use of aspirin No 64 2,586 (2,267, 2,904) - 1,078 (933, 1,223) - 1,350 (1,141, 1,560) - Yes 40 2,465 (2,221, 2,708) -4.7 0.58 977 (866, 1,088) -9.4 0.30 1,346 (1,186, 1,506) -0.3 0.98 Regulard use of other NSAID No 69 2,488 (2,152, 2,824) - 953 (801, 1,106) - 1,395 (1,175, 1,475) - YesCurrently smoke No 35 96 2,523 2,538 (2,293, 2,754) (2,349, 2,726) 1.4 - 0.87 1,048 1,029 (943, 1,152) (943, 1,115) 9.9 - 0.34 1,324 1,358 (1,172, 1,475) (1,234, 1,482) -5.2 - 0.61 Moderate 38 2,545 (2,204, 2,886) 4.9 1,027 (872, 1,183) 1.6 1,366 (1,143, 1,589) 8.4 High 27 2,518 (2,206, 2,830) 3.8 0.74 1,002 (859, 1,144) -1.0 0.91 1,375 (1,171, 1,580) 9.1 0.52 Body mass index (kg/m2) <25.0 22 2,477 (2,047, 2,907) - 986 (789, 1,182) - 1,360 (1,077, 1,642) - 25.0 - 29.9 43 2,575 (2,270, 2,880) 4.0 1,046 (907, 1,186) 6.1 1,379 (1,179, 1,579) 1.4 ≥30 Total energy, tertiles 1 39 34 2,461 2,813 (2,139, 2,782) (2,476, 3,149) 0.1 - 0.89 999 1,116 (852, 1,146) (960, 1,271) 1.4 - 0.99 1,307 1,548 (1,096, 1,518) (1,327, 1,768) -3.9 - 0.73 2 35 2,355 (2,017, 2,692) -16.3 937 (781, 1,094) -16.0 1,279 (1,058, 1,500) -17.4 3 Saturated fat, tertiles 1 35 34 2,388 2,756 (2,057, 2,719) (2,424, 3,089) -15.1 - 0.08 1,003 1,116 (850, 1,156) (961, 1,270) -10.1 - 0.31 1,230 1,482 (1,014, 1,447) (1,266, 1,698) -20.5 - 0.05 2 35 2,571 (2,238, 2,905 -6.7 974 (820, 1,129) -12.7 1,461 (1,244, 1,678) -1.4 3 Total fat, tertiles 1 35 34 2,203 2,602 (1,844, 2,562) (2,267, 2,938) -20.1 - 0.04 960 1,047 (794, 1,126) (891, 1,203) -14.0 - 0.17 1,094 1,406 (861, 1,327) (1,189, 1,623) -26.2 - 0.03 2 35 2,667 (2,335, 2,999) 2.5 1,027 (873, 1,182) -1.9 1,497 (1,283, 1,711) 6.5 3 35 2,256 (1,915, 2,596) -13.3 0.17 972 (814, 1,131) -7.1 0.52 1,132 (912, 1,352) -19.5 0.10 Totale vi...
Table S2. Inter-rater agreement a according to RSNA imaging classification for COVID-19 pneumonia diagnosis. Observer 1 - first analysis vs. Observer 2 - first analysis RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 24(15.1) 0(0.0) 3(1.9) 5(3.1) 32(20.1) .007 0.744 Typical 0(0.0) 77(48.4) 2(1.3) 0(0.0) 79(49.7) Indeterminate 0(0.0) 5(3.1) 18(11.3) 10(6.3) 33(20.8) Atypical 1(0.6) 0(0.0) 1(0.6) 13(8.2) 15(9.4) Total 25(15.7) 82(51.6) 24(15.1) 28(17.6) 159(100.0) RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 24(15.1) 1(0.6) 4(2.5) 7(4.4) 36(22.6) .001 0.725 Typical 0(0.0) 77(48.4) 2(1.3) 0(0.0) 79(49.7) Indeterminate 0(0.0) 4(2.5) 17(10.7) 9(5.7) 30(18.9) Atypical 1(0.6) 0(0.0) 1(0.6) 12(7.5) 14(8.8) Total 25(15.7) 82(51.6) 24(15.1) 28(17.6) 159(100.0) RSNA CT classification, No. (%) Negative Typical Indeterminate Atypical Total P value Xxxxx’x kappa Negative 26(16.4) 0(0.0) 0(0.0) 1(0.6) 27(17.0) .05 0.772 Typical 0(0.0) 78(49.1) 3(1.9) 0(0.0) 81(50.9) Indeterminate 4(2.5) 1(0.6) 21(13.2) 4(2.5) 30(18.9) Atypical 2(1.3) 0(0.0) 9(5.7) 10(6.3) 21(13.2) Total 32(20.1) 79(49.7) 33(20.8) 15(9.4) 159(100.0)
Table S2. Inter-rater agreement a according to RSNA imaging classification for COVID-19 pneumonia diagnosis (continued).
Table S2. Measurement Summary of 3-Facet RSM (Integrated Data, All Scorers)
Table S2. Agreement between maternal report and medical record for rheumatoid arthritis, according to time period, among women with rheumatoid arthrtis with both obstetrician and rheumatologist records available (n = 154).
Table S2. Detection of CLL recurrence by quantitative real-time PCR Months After End of CFAR Treatment Donor CLL HCDR3 (CT ) GAPDH (CT) ΔCT Δ(ΔCT) Fold Change CLL HCDR3 Detection 38 not detectable 18.7 ± 0.1 0.00 0 0 negative 51 37.48 25.4 ± 0.4 12.10 2.02 0.25 weak positive 56 26.4 ± 0.1 18.4 ± 0.2 8.02 -2.02 4.05 positive Table S2: Detection of CLL recurrence by quantitative real-time PCR. Cryopreserved MNCs from the CLL donor after treatment were analyzed by qPCR for the presence of CLL donor HCDR3 transcript. Each time point is calculated as months after end of CFAR treatment regimen. The CT , ΔCT, and Δ(ΔCT) of the qPCR reaction using the CLL donor HCDR3-specific probe and GAPDH probes were used to calculate the fold change in the CLL donor HCDR3 transcript relative to the GAPDH endogenous control. Data generated by X-J. Yan.
Table S2. Concordance and agreement (Xxxxx’x kappa) between tuberculin skin testing and QuantiFERON-TB Gold In Tube, considering ≥5 mm a TST positive in non- BCG-vaccinated and ≥10 mm in BCG-vaccinated children.
Table S2. Platelet P-selectin mean fluorescent intensity (MFI) under basal and stimulated conditions, in whole blood collected into either BD Vacutainers containing 0.109mol/l buffered sodium citrate or manual syringes preloaded with 0.109mol/l buffered sodium citrate. Syr: syringe driven aspiration; Vac: vacutainer driven aspiration; ADP: adenosine diphosphate. Values are shown as mean and 95% CI. Significance at P<.00125 (after Bonferroni correction).
